Association between viral hepatitis infection and Parkinson's disease: A population-based prospective study.
Parkinson's disease
Viral hepatitis B
Viral hepatitis C
competing risk
prospective studies
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
07
08
2019
revised:
27
04
2020
accepted:
27
05
2020
pubmed:
20
6
2020
medline:
26
8
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
The association between hepatitis virus infection and Parkinson's disease remains controversial. To determine whether hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are associated with an increased risk of Parkinson's disease in Korean aged ≥40 years, we completed a population-based prospective study including patients without infections and those with HBV, HCV and HBV/HCV infections from 2005 to 2015. We used the International Classification of Diseases 10th Revision to identify Parkinson's disease (G20) and chronic hepatitis C virus (B18.2) and chronic hepatitis B virus infections (B18.0 or B18.1). To identify Parkinson's disease risk, competing risk analysis adjusted for age, sex, comorbidities and death was performed. Overall, 1 010 317 patients (358 052, noninfection; 488 990, hepatitis B; 144 459 hepatitis C; and 18 680 hepatitis B/C) were included. The incidence density of Parkinson's disease per 10 000 person-years was highest in the hepatitis C group (8.0), followed by the hepatitis B/C (6.8) and hepatitis B (5.0) groups. Hypertension, ischaemic heart disease, epilepsy, stroke and depressive disorder increased the hazard of Parkinson's disease in all groups. The adjusted hazard ratios were 1.25 (95% confidence interval: 1.17-1.35), 1.39 (95% confidence interval: 1.27-1.52) and 1.46 (95% confidence interval: 1.14-1.85) in the HBV, HCV, and HBV/HCV groups, respectively. Our findings suggest that adult patient of 40 years and older with HBV and HCV infections should be monitored for signs of Parkinson's disease so that early intervention and accurate treatment can be provided for minimizing the development and consequences of Parkinson's disease.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1171-1178Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Foundation P.Understanding Parkionson's: Statistics. Understanding Parkionson's 2018. http://parkinson.org/Understanding-Parkinsons/Causes-and-Statistics/Statistics. Accessed February 14, 2017.
Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-905.
Wooten GF. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry. 2004;75(4):637-639.
Moisan F, Kab S, Mohamed F, et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87(9):952-957.
Pakpoor J, Noyce A, Goldacre R, et al. Viral hepatitis and Parkinson disease A national record-linkage study. Am Acad Neurol. 2017;29:210-212.
Wu WY, Kang KH, Chen SL, et al. Hepatitis C virus infection: a risk factor for Parkinson's disease. J Viral Hepat. 2015;22(10):784-791.
Tsai H-H, Liou H-H, Muo C-H, Lee C-Z, Yen R-F, Kao C-H. Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study. Neurology. 2016;86:840-846.
World Health Organization. Global hepatitis report. Geneva, Switzerland: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO).
Cheol Seong S, Kim Y-Y, Khang Y-H, et al. Data resource profile: the national health information database of the national health insurance service in South Korea. Int J Epidemiol. 2016;46(3):799-800.
Seong SC, Son MS. National Health Insurance Statistical Yearbook. Wonju: Health Insurance Review & Assessment Service, National Health Insurance Service; 2016.
Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the national health insurance service-national sample cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2016;46(2):e15.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
Wikipedia. Hepatitis B virus. 2016.
Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129(2):154-169.
Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
Zhang Y, Cobleigh MA, Lian JQ, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology. 2011;141(5):1897-1906.
Kim JM, Jang ES, Ok K, et al. Association between Hepatitis C virus infection and Parkinson's disease. Mov Disord.2016;31(10):1584-1585.
Abushouk AI, El-Husseny MWA, Magdy M, et al. Evidence for association between hepatitis C virus and Parkinson's disease. Neurol Sci. 2017;38(11):1913-1920.
Mathew S, Faheem M, Ibrahim SM, et al. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8(12):545-556.
Wijarnpreecha K, Chesdachai S, Jaruvongvanich V, Ungprasert P. Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(1):9-13.
Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of Hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599-1608.
Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431-1444.
Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244-256.